The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectable Pancreatic Adenocarcinoma
Victoria Heredia-Soto,
Laura Gutiérrez-Sainz,
Ismael Ghanem,
Laura Guerra,
Elena Palacios,
Marta de Uribe,
Lucía Trilla-Fuertes,
María de Miguel,
Paloma Cejas,
Laura Medina,
José Miguel Calderón,
David Viñal,
Marta Mendiola,
Jaime Feliu
Affiliations
Victoria Heredia-Soto
Translational Oncology Research Laboratory, Biomedical Research Institute, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
Laura Gutiérrez-Sainz
Oncology Department, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
Ismael Ghanem
Oncology Department, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
Laura Guerra
Pathology Department, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain
Elena Palacios
Pathology Department, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain
Marta de Uribe
Pathology Department, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain
Lucía Trilla-Fuertes
Molecular Oncology Lab, Instituto de Genética Médica y Molecular-INGEMM, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain
María de Miguel
Translational Oncology Research Laboratory, Biomedical Research Institute, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
Paloma Cejas
Translational Oncology Research Laboratory, Biomedical Research Institute, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
Laura Medina
UGCI Medical Oncology Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, 29010 Málaga, Spain
José Miguel Calderón
Pathology Department, Fuenlabrada University Hospital, 28942 Madrid, Spain
David Viñal
Oncology Department, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
Marta Mendiola
Translational Oncology Research Laboratory, Biomedical Research Institute, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
Jaime Feliu
Oncology Department, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
GATA4 and GATA6 are transcription factors involved in the differentiation and development of PDAC. GATA6 expression is related to the classic molecular subtype, while its absence is related to the basal-like molecular subtype. The aim was to determine the clinical utility of IHC determination of GATA4 and GATA6 in a series of patients with resected PDAC. GATA4 and GATA6 expression was studied by IHC in TMA samples of normal tissue, PanIN, tumor tissue and lymph node metastases from a series of 89 patients with resected PDAC. Its relationship with clinicopathologic variables and the outcome was investigated. Seventy-two (81%) tumors were GATA6+ and 37 (42%) were GATA4+. While GATA4 expression was reduced during tumor progression, GATA6 expression remained highly conserved, except in lymph node metastases. All patients with early stages and well-differentiated tumors were GATA6+. The absence of GATA4 expression was related to smoking. Patients with GATA4+ or GATA6+ tumors had significantly lower Ca 19.9 levels. The expression of GATA4 and GATA6 was related to DFS, being more favorable in the GATA4+/GATA6+ group. The determination of the expression of GATA4 and GATA6 by IHC is feasible and provides complementary clinical and prognostic information that can help improve the stratification of patients with PDAC.
